...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in Vascular Medicine >Perioperative Hemodynamic Management and Pharmacotherapeutics of Patients Undergoing Thoracic Endovascular Aortic Repair
【24h】

Perioperative Hemodynamic Management and Pharmacotherapeutics of Patients Undergoing Thoracic Endovascular Aortic Repair

机译：胸腔内血管主动脉修复患者的围手术期血流动力学管理和药物治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Thoracic endovascular aortic repair (TEVAR) has become an attractive alternative treatment option for many patients with specific thoracic aortic disease. New devices and advanced image-guided procedures are continuously expanding the indications and improve neurological outcomes. Hemodynamic management of these patients is a critical aspect in reducing neurological deficit and it is different compared to patients undergoing open thoracic aortic operations. There are two different phases of blood pressure management for patients with thoracic aortic disease. Before and during the critical steps of TEVAR anti-impulsive therapy facilitates safe positioning and stent deployment. After stent grafts are deployed, controlled hypertensive blood pressure levels are achieved to avoid spinal cord ischemia. This precise blood pressure strategy is essential to ensure a safe procedure and good long-term results.
机译：胸腔内血管主动脉修复术（TEVAR）已成为许多特定胸主动脉疾病患者的有吸引力的替代治疗选择。新设备和先进的图像引导程序正在不断扩大适应症并改善神经系统结局。这些患者的血流动力学管理是减少神经功能缺损的关键方面，与接受开胸主动脉手术的患者相比，这是不同的。胸主动脉疾病患者的血压管理分为两个不同的阶段。在TEVAR抗冲治疗的关键步骤之前和之中，有助于安全定位和支架部署。部署支架移植物后，可达到控制的高血压水平，以避免脊髓缺血。这种精确的血压策略对于确保安全的程序和良好的长期效果至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号